Literature DB >> 32431378

Systematic Review of Ovarian Activity and Potential for Embryo Formation and Loss during the Use of Hormonal Contraception.

Donna Harrison1, Cara Buskmiller2, Monique Chireau3, Lester A Ruppersberger4, Patrick P Yeung2.   

Abstract

The purpose of this review was to determine whether there is evidence that ovulation can occur in women using hormonal contraceptives and whether these drugs might inhibit implantation. We performed a systematic review of the published English-language literature from 1990 to the present which included studies on the hormonal milieu following egg release in women using any hormonal contraceptive method. High circulating estrogens and progestins in the follicular phase appear to induce dysfunctional ovulation, where follicular rupture occurs but is followed by low or absent corpus luteum production of progesterone. Hoogland scoring of ovulatory activity may inadvertently obscure the reality of ovum release by limiting the term "ovulation" to those instances where follicular rupture is followed by production of a threshold level of luteal progesterone, sufficient to sustain fertilization, implantation, and the end point of a positive β-human chorionic gonadotropin. However, follicular ruptures and egg release with subsequent low progesterone output have been documented in women using hormonal contraception. In the absence of specific ovulation and fertilization markers, follicular rupture should be considered the best marker for egg release and potential fertilization. Women using hormonal contraceptives may produce more eggs than previously described by established criteria; moreover, suboptimal luteal progesterone production may be more likely than previously acknowledged, which may contribute to embryo loss. This information should be included in informed consent for women who are considering the use of hormonal contraception.
SUMMARY: For this study, the authors looked at English-language research articles that focused on how hormonal birth control, such as the birth control pill, may affect very early human embryos. The authors found that abnormal ovulation, or release of an egg followed by abnormal hormone levels, may often occur in women using hormonal birth control. This may increase the number of very early human embryos who are lost before a pregnancy test becomes positive. For women who are thinking about using hormonal birth control, this is important information to consider. © Catholic Medical Association 2018.

Entities:  

Keywords:  Bioethics of emergency contraceptives; Contraception; Emergency contraception; Ethics of reproduction; Fertility awareness; Oral contraception; Plan B; Rape protocols; Rights of conscience

Year:  2019        PMID: 32431378      PMCID: PMC6322118          DOI: 10.1177/0024363918815611

Source DB:  PubMed          Journal:  Linacre Q        ISSN: 0024-3639


  55 in total

1.  Suppression of ovarian activity with a low-dose 21/7-day regimen oral contraceptive containing ethinylestradiol 20 mcg/drospirenone 3 mg in Japanese and Caucasian women.

Authors:  Yuzuru Anzai; Doris Heger-Mahn; Ilka Schellschmidt; Joachim Marr
Journal:  Contraception       Date:  2012-03-06       Impact factor: 3.375

Review 2.  Improving the luteal phase after ovarian stimulation: reviewing new options.

Authors:  C Yding Andersen; K Vilbour Andersen
Journal:  Reprod Biomed Online       Date:  2014-02-05       Impact factor: 3.828

3.  Feasibility study of Nestorone-ethinylestradiol vaginal contraceptive ring for emergency contraception.

Authors:  Horatio B Croxatto; Vivian Brache; Rebecca Massai; Francisco Alvarez; M L Forcelledo; Margarita Pavez; Leila Cochon; Ana Maria Salvatierra; Aníbal Faundes
Journal:  Contraception       Date:  2005-11-14       Impact factor: 3.375

Review 4.  Current issues and available options in combined hormonal contraception.

Authors:  Johannes Bitzer; James A Simon
Journal:  Contraception       Date:  2011-04-27       Impact factor: 3.375

5.  Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.

Authors:  J Spona; W Feichtinger; C Kindermann; C Moore; U Mellinger; F Walter; T Gräser
Journal:  Contraception       Date:  1997-09       Impact factor: 3.375

6.  GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism.

Authors:  Samer Tannus; Yechiel Burke; Christopher R McCartney; Shahar Kol
Journal:  Gynecol Endocrinol       Date:  2017-04-25       Impact factor: 2.260

7.  Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study.

Authors:  Jan Endrikat; Susanne Parke; Dietmar Trummer; Marco Serrani; Ingrid Duijkers; Christine Klipping
Journal:  Contraception       Date:  2012-09-17       Impact factor: 3.375

Review 8.  Endometrial receptivity markers, the journey to successful embryo implantation.

Authors:  Hanna Achache; Ariel Revel
Journal:  Hum Reprod Update       Date:  2006-09-18       Impact factor: 15.610

9.  A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation.

Authors:  Robin Kroll; Larry Seidman; Nancy Ricciotti; Brandon Howard; Herman Weiss
Journal:  Eur J Contracept Reprod Health Care       Date:  2014-12-19       Impact factor: 1.848

10.  Increased incidence and recurrence of recent corpus luteum without ovulation stigma (luteinized unruptured follicle syndrome?) in baboons with endometriosis.

Authors:  T M D'Hooghe; C S Bambra; B M Raeymaekers; P R Koninckx
Journal:  J Soc Gynecol Investig       Date:  1996 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.